TENAX THERAPEUTICS, INC. Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31)
TENAX THERAPEUTICS, INC. (TENX) had Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31) of $43.73 thousand as of 2013-01-31, per its 10-Q filed 2013-03-18.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationNoncurrentLiabilitiesRestructuringCostAccrual · last filed 2013-03-18
- 2013-01-31: Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31) $43.73K.
- 2012-10-31: Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31) $43.73K.
- 2012-07-31: Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31) $13.83K.
| Period end | Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Restructuring Cost Accrual (Deprecated 2013-01-31) |
|---|---|
| 2013-01-31 | $43.73K 10-Q · filed 2013-03-18 |
| 2012-10-31 | $43.73K 10-Q · filed 2012-12-14 |
| 2012-07-31 | $13.83K 10-Q · filed 2012-09-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |